Editorials

Coronary artery disease: screen or treat?

BMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i1395 (Published 17 March 2016) Cite this as: BMJ 2016;352:i1395
  1. Darrel P Francis, professor,
  2. Graham D Cole, specialty registrar
  1. International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London W2 1LA, UK
  1. Correspondence to: D Francis d.francis{at}imperial.ac.uk

Effective drug therapy is available without prescription and may even be cheaper than the screening test itself

The central argument of The Widowmaker, a controversial US documentary attacking interventional cardiologists,1 is that computed tomographic (CT) calcium scoring could be used to screen the apparently healthy population and prevent thousands of deaths from heart attack. However, screening is not prevention; it is a method of rationing preventive interventions that would be too unpleasant or expensive to offer to all. The scans themselves are not treatment; they do not prolong lives.

Coronary artery disease is unusual in that effective preventive treatment has been established by randomised controlled trials. For example, statins under blinded evaluation seem to cause no more symptoms than placebo2 and reduce rates of myocardial infarction or death from coronary disease—for example, by 31% in middle aged men with high cholesterol.3 Their five year event rate was reduced from 7.9% to 5.5%, an absolute risk reduction of 2.4%. The limited period of randomisation prevents trials showing effects of a lifetime of therapy. Mathematical studies can overcome this by calculating average expected lifespan extension, which is about nine months for 50 year olds with the distribution of risk …

View Full Text

Sign in

Log in through your institution

Subscribe